Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
企業コードEYEN
会社名Hyperion DeFi Inc
上場日Jan 25, 2018
設立日2014
最高経営責任者「CEO」Mr. Michael M. Rowe
従業員数13
証券種類Ordinary Share
決算期末Jan 25
本社所在地295 Madison Ave Ste 2400
都市NEW YORK
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号10017
電話番号18137669539
ウェブサイトhttps://eyenovia.com/
企業コードEYEN
上場日Jan 25, 2018
設立日2014
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし